M
Mikhail Byakhov
Publications - 11
Citations - 895
Mikhail Byakhov is an academic researcher. The author has contributed to research in topics: Paclitaxel & Allosteric regulation. The author has an hindex of 7, co-authored 11 publications receiving 766 citations.
Papers
More filters
Journal ArticleDOI
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni,Wolfgang Eiermann,Vladimir Semiglazov,Ana Lluch,Sergei Tjulandin,Milvia Zambetti,Angela Moliterni,Federico Vazquez,Mikhail Byakhov,Mikhail Lichinitser,Miguel Angel Climent,Eva Ciruelos,Belén Ojeda,Mauro Mansutti,Bozhok Aa,Domenico Magazzu,Dominik Heinzmann,Jutta Steinseifer,Pinuccia Valagussa,José Baselga +19 more
TL;DR: These results show a sustained benefit in event-free survival from trastuzumab-containing neoadjuvant therapy followed by adjuvant trastzumab in patients with locally advanced or inflammatory breast cancer, and provide new insight into the association between pathological complete remission and long-term outcomes in HER2-positive disease.
Journal ArticleDOI
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Luca Gianni,José Baselga,Wolfgang Eiermann,Vincente Guillem Porta,Vladimir Semiglazov,Aňa Lluch,Milvia Zambetti,Dolores Sabadell,Günther Raab,Antonio Llombart Cussac,Bozhok Aa,Angel Martinez-Agulló,Marco Greco,Mikhail Byakhov,JJ López,Mauro Mansutti,Pinuccia Valagussa,Gianni Bonadonna +17 more
TL;DR: In this article, the authors evaluated the effect of the addition of paclitaxel to an anthracycline-based adjuvant regimen and compared this combination with the same regimen given as primary systemic (neoadjuvant) therapy.
Journal ArticleDOI
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
Luca Gianni,José Baselga,Wolfgang Eiermann,Vicente Guillem Porta,Vladimir Semiglazov,Ana Lluch,Milvia Zambetti,Dolores Sabadell,Günther Raab,Antonio Llombart Cussac,Bozhok Aa,Angel Martinez-Agulló,Marco Greco,Mikhail Byakhov,JJ López,Mauro Mansutti,Pinuccia Valagussa,Gianni Bonadonna +17 more
TL;DR: Doxorubicin/paclitaxel → CMF is feasible, safe, and well tolerated, allowing for breast-sparing surgery in a large fraction of patients, given as PST.
Journal ArticleDOI
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
José Baselga,José Baselga,Alexey Manikhas,Javier Cortes,Javier Cortes,Antonio Llombart,L Roman,Vladimir Semiglazov,Mikhail Byakhov,D. Lokanatha,S. Forenza,R.H. Goldfarb,J. Matera,N. Azarnia,Clifford A. Hudis,M. Rozencweig +15 more
TL;DR: The trial failed to demonstrate a significant clinical improvement with the addition of M to TP regimen, and the clinical benefit observed in an exploratory analysis in the ER- and PR-negative population deserves consideration for further clinical trials.
Journal ArticleDOI
Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models.
Ilya Tsimafeyeu,John H. Ludes-Meyers,Evgenia Stepanova,Frits Daeyaert,Dmitry Khochenkov,Jean-Baptiste Joose,Eliso Solomko,Koen Van Akene,Nina Peretolchina,Wei Yin,Oxana Ryabaya,Mikhail Byakhov,Sergei Tjulandin +12 more
TL;DR: Results show that alofanib is a potent FGFR2 inhibitor and provide strong rationale for its evaluation in patients withFGFR2-driven cancers.